If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
128
results.
Updated on
13/07/2025 [07:35:00]
Results 50 to 75 of 128
Absstract of: EP4537847A2
Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to inflammation, such as necrotizing enterocolitis, mesenteric ischemia, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, lymphocytic colitis, Celiac disease, Behcet's disease, rheumatoid arthritis, psoriasis, and autoimmune thyroid disease.
Absstract of: CN119818682A
The invention belongs to PDIA1, and particularly relates to application of PDIA1 as a drug screening target in preparation of drugs for treating ulcerative colitis. The technical problem to be solved by the invention is to provide a new molecular target for recovery of intestinal epithelial barriers in ulcerative colitis. The expression level of PDIA1 in epithelial cells of patients with ulcerative colitis is higher than that of healthy people, and symptoms of ulcerative colitis can be effectively improved by inhibiting PDIA1. The invention provides a new thought for further researching the intestinal epithelial barrier recovery mechanism and the medical application of the PDIA1.
Absstract of: WO2025076081A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Absstract of: US2025114413A1
The present disclosure relates to a formulation for supporting the growth or maintenance of bacteria in the gastrointestinal tract of an animal. Provided is the use of at least one human milk oligosaccharide in combination with pre-biotics and probiotic strains of bacteria for the manufacture of a food composition, pharmaceutical composition, food or dietary supplement, for the selective stimulation of beneficial bacteria in the gastrointestinal tract in context of a disease condition. Also provided is a synbiotic formulation comprising living beneficial bacteria formulated with at least one human milk oligosaccharide in combination with pre-biotics. In particular, synbiotic formulation is used for improving clinical biomarkers in diseases especially Crohn's disease.
Absstract of: WO2025076414A1
The disclosure provides methods for predicting response in a subject having IBD to anti-IL12 and/or anti-IL23-based therapies, and selecting an effective therapy.
Absstract of: WO2025075714A1
Described herein is a method of diagnosing and/or treating irritable bowel syndrome (IBS) in a subject. The method comprises determining a fatty acid profile in a stool sample of the subject; and comparing the fatty acid profile with a first reference profile indicating an absence of IBS or a second reference profile indicating IBS. Also described herein is a composition for treating IBS, which comprises two or more of a Monoglobaceae bacterium, a Lachnospiraceae bacterium; and a Ruminococcaceae bacterium, as well as a method of treating IBS using the same.
Absstract of: AU2023276693A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Absstract of: CN119776531A
The invention relates to application of an SNTB1 gene in occurrence and development of colorectal cancer caused by colitis and proctitis. The key effect of the SNTB1 gene in occurrence and development of colorectal cancer caused by colorectal cancer is creatively disclosed, a new perspective is provided for pathogenesis and molecular fundamental research of colorectal cancer, and development of targeted treatment strategies or prevention methods is facilitated. And secondly, the SNTB1 gene is used as a biomarker, so that effective screening of colitis cancer transformation high-risk groups can be realized, and the early diagnosis rate is improved. Besides, the SNTB1 gene expression promoter provided by the invention can be used for constructing a whole-process animal model for colorectal cancer transformation, and a powerful tool is provided for deeply researching pathogenesis of colorectal cancer and screening drugs. Meanwhile, the prepared preventive pharmaceutical composition is expected to effectively prevent transformation of colitis and proctitis cancers by inhibiting SNTB1 gene expression.
Absstract of: CN119780430A
The invention discloses an application of a response marker for treating ulcerative colitis by coprophilous fungi transplantation, and belongs to the technical field of biology, as a further optimization scheme of the invention, the coprophilous fungi comprise Streptococcus, Faecalibacteria, Weissella, Lactococcus and Rombout, and the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation has the advantages that the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation is realized, and the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation is realized. As a further optimization scheme of the invention, the coprophilous bacteria further comprise Streptococcus pluviae, Bifidobacterium longum, Lactococcus garviae, Weissella parasites, Lactococcus fermentum and Lactococcus lactis, and the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae and the In the invention, the flora change before and after coprophilous fungus transplantation treatment is researched on a pati
Absstract of: US2025109210A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Absstract of: US2025109209A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Absstract of: CN119724354A
The invention discloses a screening method and application of an ulcerative colitis biomarker, EPHX2 can be used as a biomarker for ulcerative colitis detection, provides a new technical means for ulcerative colitis detection, diagnosis, treatment and prognosis evaluation, provides a new direction for research of UC pathogenesis, and provides a new application prospect. And a new possibility is provided for clinical treatment.
Absstract of: US2025104866A1
A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.
Absstract of: WO2025064645A1
The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease (IBD) and to physiologically acceptable compositions of isolated bacterial strains, lysates thereof, and supernatants therefrom for use in treating IBD.
Absstract of: WO2025064813A1
A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.
Absstract of: CN119255775A
A defecation detection and alert system includes a sensing device mounted to an absorbent article for alerting a caregiver of the presence of solid excreta by analyzing gas expelled from the absorbent article during defecation. The system includes an elongate conduit made of a flexible material and mounted to an absorbent article. The pipeline is connected to a gas sensor arranged in the hanging device, and the gas sensor determines whether defecation occurs in the absorption product or not by detecting existence of hydrogen sulfide gas.
Absstract of: CN119693421A
The invention discloses a mouse intestinal peristalsis speed detection method and device based on a fluid dense optical flow algorithm, and the method specifically comprises the steps: carrying out the dyeing imaging of a mouse intestinal tract, and shooting a mouse intestinal peristalsis video; carrying out calculation region framing on the complete mouse intestine peristalsis video, extracting an intestine region contour of the mouse, and framing a rectangular image region needing to be calculated; the method comprises the following steps: preprocessing a mouse intestine peristalsis video, filtering breathing frames frame by frame, marking frames influenced by breathing as invalid frames, and skipping in subsequent optical flow calculation; performing optical flow calculation: circularly reading every two frames of the video, and obtaining a group of optical flows after respiration influence is eliminated by using a fluid-based dense optical flow algorithm; and (n-1) groups of optical streams obtained by the n frames of videos are superposed along a time axis to obtain an optical stream index at each pixel point in the whole intestinal region so as to determine the intestinal peristalsis speed of the mouse. The mouse intestinal tract can be monitored in real time and repeatedly evaluated, and theoretical support is provided for diagnosing inflammatory bowel diseases and discovering potential therapeutic drugs.
Absstract of: CN119685466A
The invention discloses an application of DUOX2 in identification of ileum subtype and colon subtype Crohn's disease. A group of new DUOX2-epi is analyzed and identified based on single cell transcriptome sequencing, the proportion of the cells in the Crohn disease inflammation tissue is obviously increased, and the proportion of the DUOX2-epi in the colon type Crohn disease inflammation tissue is obviously higher than that in the ileum type Crohn disease inflammation tissue; in addition, in ileum type and colon type Crohn diseases, interaction with surrounding cells is carried out through different mechanisms, so that the occurrence and development of the diseases are promoted. Therefore, based on a DUOX2-epi mediated intercellular communication network, a gene prediction module for predicting different subtypes of Crohn diseases and evaluating the treatment effect of a biological agent is developed, and based on a DUOX2 molecular network, an experimental basis and a research direction are provided for subsequent in-depth research, and a new strategy is expected to be provided for diagnosis and treatment of different subtypes of Crohn diseases.
Absstract of: CN119666500A
The invention provides a biomarker for predicting whether an individual suffers from progression-stage adenoma or not and application of the biomarker. Proteins with significantly different abundance levels in blood of patients and healthy control people at different stages in the colorectal cancer tumor process (inflammatory disease-benign polyp-progression-stage adenoma-colorectal cancer) are analyzed, and a plurality of protein markers capable of being used for progression-stage adenoma risk prediction are screened out. On one hand, a dichotomy algorithm is adopted, a model is built based on a random forest, good performance is shown in distinguishing of progression-stage adenoma and healthy control, the AUC value reaches 0.807, and high diagnostic value is achieved; a six-classification algorithm is further adopted, a model is constructed through gradient lifting, progressive-stage adenoma, early-stage colorectal cancer, benign polyp, inflammatory bowel disease, other cancers and healthy people can be effectively distinguished, the accuracy of the model is 0.78, the consistency is 0.729, the diagnosis sensitivity of the progressive-stage adenoma is 73.4%, and the specificity is 94.7%; and a new way is provided for progression stage adenoma diagnosis.
Absstract of: US2025090497A1
Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopentabindol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Absstract of: EP4523694A1
The present disclosure relates to: a method, a composition, and a method for producing the same for treating IBD using gastrointestinal contents or excretions modified with an IgA antibody; a method for obtaining an IgA antibody that restores the bacterial flora in the gastrointestinal tract of an IBD patient; a method, a composition, and a method for producing the same for modifying gastrointestinal contents or excretions of an IBD patient using an IgA antibody; and a method, a composition, and a method for producing the same for testing with the diagnostic pharmaceutical drug containing an IgA antibody in a patient treated with the IBD therapeutic agent containing gastrointestinal contents or excretions.
Absstract of: CN119639932A
The invention discloses an application of intestinal bacteria in an ulcerative colitis prediction technology, and belongs to the technical field of biology, and the intestinal bacteria are Alistipes finegoldii; the method comprises the following steps: detecting the relative abundance of Alistipes finegii in an excrement sample of a patient, and using the low relative abundance of Alistipes finegii to predict the disease activity of ulcerative colitis; according to the application disclosed by the invention, not only is the association between the Alistipes finegili and the UC disease activity verified, but also the potential action mechanism of the Alistipes finegili is further explored. By means of 16s amplicon sequencing and transcriptomics combined analysis, it is found that the Alistipes finegili plays an anti-inflammatory role through an Hsp90/AMPK/ACC signal channel, and the intestinal barrier function is maintained. The invention verifies that a new view angle is provided for the effect of the Alistipes finegili in the UC pathogenesis, and provides a theoretical basis for developing a treatment strategy based on the strain.
Absstract of: CN119619519A
The invention relates to application of a C7orf10 protein level detection agent in preparation of a mitochondrial disease diagnostic agent. Research finds that C7orf10 protein level rise is shown in cells with mitochondrial dysfunction caused by different gene defects and in the body of a patient, which indicates that the C7orf10 protein level rise can be used as a molecular marker of the mitochondrial dysfunction, so that a C7orf10 protein level detection agent can be used as a mitochondrial disease diagnosis agent, and the clinical application prospect is wide. Therefore, a novel diagnosis method and a novel diagnosis reagent are provided for diagnosis of mitochondrial diseases.
Absstract of: CN119613546A
The invention discloses an IL-10 antibody and an application thereof. The anti-human IL-10 monoclonal antibody human IL-10 protein provided by the invention has relatively strong affinity, can be used for detecting the expression of the human IL-10 protein, can also be applied to immunotherapy independently or in combination with other methods, and has diagnosis and treatment values in tumors, inflammatory bowel diseases and rheumatism immune diseases.
Nº publicación: US2025084174A1 13/03/2025
Applicant:
MEDIMMUNE LTD [GB]
MedImmune Limited
Absstract of: US2025084174A1
The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.
BOPI
Electronic site
